Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Defining Reversal of Keloid Lesions by Th2 Targeting With Dupilumab Treatment

NCT04988022 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT04988022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04988022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Defining Reversal of Keloid Lesions by Th2 Targeting With Dupilumab Treatment
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 4
Overall status
Completed
Start date
May 25, 2021
Completion date
March 24, 2025
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

keloid